Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

(2009) D. H. Kim et al.   CLINICAL CANCER RESEARCH

Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group

(2009) Mari Sakai et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR

(2009) Masahide Yamamoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia

(2009) J E Cortes et al.   LEUKEMIA

Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter?

(2008) Yoshinobu Kanda et al.   AMERICAN JOURNAL OF HEMATOLOGY

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

(2008) S. Dulucq et al.   BLOOD

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

(2008) R. A. Larson et al.   BLOOD

Interaction of Imatinib with Human Organic Ion Carriers

(2008) S. Hu et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

(2008) A. Petain et al.   CLINICAL CANCER RESEARCH

Organic Cation Transporters and their Pharmacokinetic and Pharmacodynamic Consequences

(2008) Min-Koo Choi et al.   Drug Metabolism and Pharmacokinetics